Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
British Journal of Cancer
|
February 2, 2024
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer
Simon Holt, Mark Verrill, Laura Pettit, et al.
Journal of the National Cancer Institute
|
July 22, 2004
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial
Robert C F Leonard, Michael Lind, Christopher Twelves, et al.
Clinical Sarcoma Research
|
May 12, 2020
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
Spyridon Gennatas, Florence Chamberlain, Thomas Carter, et al.
Cancers
|
June 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
Chau Dang, Michael S Ewer, Suzette Delaloge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2008
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer
José Baselga, Milvia Zambetti, Antoni Llombart-Cussac, et al.
The Lancet. Oncology
|
November 5, 2023
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
Galina Velikova, James P Morden, Joanne S Haviland, et al.
BMJ Open
|
December 30, 2022
Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT)
Rebecca H Maier, Chris Plummer, Adetayo S Kasim, et al.
Breast (Edinburgh, Scotland)
|
November 4, 2021
Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study
Salma El Badri, Bilal Tahir, Kirsty Balachandran, et al.
Lancet (London, England)
|
May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Paul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.
The Lancet. Oncology
|
June 11, 2017
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
David Cameron, James P Morden, Peter Canney, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
British Journal of Cancer
|
February 2, 2024
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer
Simon Holt, Mark Verrill, Laura Pettit, et al.
Journal of the National Cancer Institute
|
July 22, 2004
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial
Robert C F Leonard, Michael Lind, Christopher Twelves, et al.
Clinical Sarcoma Research
|
May 12, 2020
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
Spyridon Gennatas, Florence Chamberlain, Thomas Carter, et al.
Cancers
|
June 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
Chau Dang, Michael S Ewer, Suzette Delaloge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2008
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer
José Baselga, Milvia Zambetti, Antoni Llombart-Cussac, et al.
The Lancet. Oncology
|
November 5, 2023
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
Galina Velikova, James P Morden, Joanne S Haviland, et al.
BMJ Open
|
December 30, 2022
Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT)
Rebecca H Maier, Chris Plummer, Adetayo S Kasim, et al.
Breast (Edinburgh, Scotland)
|
November 4, 2021
Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study
Salma El Badri, Bilal Tahir, Kirsty Balachandran, et al.
Lancet (London, England)
|
May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Paul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.
The Lancet. Oncology
|
June 11, 2017
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
David Cameron, James P Morden, Peter Canney, et al.
Page
of 4